We develop the
drug candidate BAFA
We develop the
drug candidate BAFA
Epicyt Pharma AB
Visiting and postal address:
c/o Business Control Partner Norden AB
Krokslätts Fabriker 30, SE-431 37 Mölndal, Sweden
invoice@epicytpharma.com
Epicyt Pharma AB is a Gothenburg-based pharmaceutical R&D company whose development effort is focused on calcium absorption in the intestine and how this affects the bone health. The company was founded in 2014 when the scientist Lars Fändriks and Ville Wallenius together with a group of investors decided to exploit the discovery.
| Shares | Share and votes | |
| Almi Invest Västsverige AB | 456 619 | 16,72% |
| Göran Lundegårdh | 376 393 | 13,79% |
| Linc AB | 419 325 | 15,36% |
| Villus AB | 256 000 | 9,38% |
| BENF AB | 256 000 | 9,38% |
| Habeco AB | 213 000 | 7,80% |
| Abonja AB | 203 280 | 7,44% |
| Henry Myrgren | 86 322 | 3,16% |
| Strategic Wisdom Nordic AB | 75 149 | 2,75% |
| Forsed Holding AB | 63 460 | 2,32% |
| Almi Invest AB | 62 226 | 2,28% |
| GU-Ventures | 48 809 | 1,79% |
| 12 largest shareholders | 2 516 583 | 92,17% |
| Other | 213 878 | 7,83% |
| Total | 2 730 461 | 100% |